KYMR - Kymera Therapeutics, Inc.

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 45.4

Open

Bid

$ 45.35 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 9.60 - $ 50.19

Volume

276,784

Average Volume

Market Cap

2.8B

Beta (5Y Monthly)

$ 2.15

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2024	06-30-2024	10-Q
2	05-02-2024	03-31-2024	10-Q
3	02-22-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-04-2023	03-31-2023	10-Q
7	02-23-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-03-2022	03-31-2022	10-Q
11	02-24-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-06-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	03-11-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

this-bjs-wholesale-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-monday

This BJ's Wholesale Analyst Is No Longer B...
08/26/2024 13:00:41

Wolfe Research Upgrades Kymera Therapeutic...
08/26/2024 10:26:15

Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform and announces $6...

Kymera Therapeutics Raises $225M Via Upsiz...
08/20/2024 06:46:11

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule med...

Kymera Therapeutics Begins Public Offering...
08/19/2024 20:02:52

All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition,...

Morgan Stanley Maintains Equal-Weight on K...
08/14/2024 11:57:33

Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price ta...

Unveiling 6 Analyst Insights On Kymera The...
08/12/2024 21:01:08

Wells Fargo Maintains Equal-Weight on Kyme...
08/12/2024 17:43:23

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price targe...

Kymera Therapeutics' Cash Balance Of $702M...
08/07/2024 11:02:57

Kymera Therapeutics Q2 2024 GAAP EPS $(0.5...
08/07/2024 11:01:48

xpeng--quantumscape-are-among-top-11-mid-cap-stocks-that-performed-well-last-week-july-7-july-13-details

XPeng & QuantumScape Are Among Top 11 Mid ...
07/14/2024 17:22:37

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeut...

Oppenheimer Maintains Outperform on Kymera...
07/10/2024 17:49:15

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and maintains $52 price target.

B. Riley Securities Maintains Neutral on K...
07/09/2024 17:59:41

B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Neutral and raises the price tar...

why-helen-of-troy-shares-are-trading-lower-by-around-30-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Helen of Troy Shares Are Trading Lower...
07/09/2024 16:59:31

nvidia-micron-arlo-technologies-and-other-big-stocks-moving-higher-on-tuesday

Nvidia, Micron, Arlo Technologies And Othe...
07/09/2024 14:05:05

Kymera Intends To Expand Hidradenitis Supp...
07/08/2024 20:06:22

Cracking The Code: Understanding Analyst R...
06/17/2024 12:00:57

HC Wainwright & Co. Reiterates Buy on Kyme...
06/17/2024 10:52:48

HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $46 price ...

Kymera Therapeutics Shares New Clinical Da...
06/14/2024 11:21:47

HC Wainwright & Co. Reiterates Buy on Kyme...
06/03/2024 10:54:19

HC Wainwright & Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $46 price ...

Reported Saturday, Kymera Therapeutics Sho...
06/03/2024 08:40:53

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical model...